Goldman Sachs’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1B | Buy |
1,300,558
+203,231
| +19% | +$156M | 0.12% | 168 |
|
|
2025
Q4 | $847M | Buy |
1,097,327
+144,488
| +15% | +$98.1M | 0.1% | 166 |
|
|
2025
Q3 | $536M | Buy |
952,839
+156,633
| +20% | +$88.6M | 0.07% | 279 |
|
|
2025
Q2 | $418M | Sell |
796,206
-40,887
| -5% | -$22.8M | 0.06% | 335 |
|
|
2025
Q1 | $531M | Buy |
837,093
+192,456
| +30% | +$132M | 0.09% | 234 |
|
|
2024
Q4 | $459M | Buy |
644,637
+35,594
| +6% | +$29.9M | 0.07% | 248 |
|
|
2024
Q3 | $640M | Sell |
609,043
-79,536
| -12% | -$88.5M | 0.1% | 184 |
|
|
2024
Q2 | $724M | Buy |
688,579
+307,658
| +81% | +$298M | 0.12% | 155 |
|
|
2024
Q1 | $367M | Buy |
380,921
+9,136
| +2% | +$8.69M | 0.07% | 308 |
|
|
2023
Q4 | $327M | Sell |
371,785
-21,385
| -5% | -$17.6M | 0.06% | 332 |
|
|
2023
Q3 | $324M | Sell |
393,170
-108,860
| -22% | -$85.6M | 0.07% | 266 |
|
|
2023
Q2 | $361M | Buy |
502,030
+66,252
| +15% | +$51.1M | 0.08% | 243 |
|
|
2023
Q1 | $358M | Sell |
435,778
-126,927
| -23% | -$95.7M | 0.08% | 243 |
|
|
2022
Q4 | $406M | Buy |
562,705
+130,790
| +30% | +$96.5M | 0.1% | 198 |
|
|
2022
Q3 | $298M | Buy |
431,915
+16,790
| +4% | +$10.6M | 0.08% | 251 |
|
|
2022
Q2 | $245M | Buy |
415,125
+37,578
| +10% | +$24.4M | 0.06% | 318 |
|
|
2022
Q1 | $264M | Buy |
377,547
+1,902
| +0.5% | +$1.2M | 0.06% | 343 |
|
|
2021
Q4 | $237M | Sell |
375,645
-77,147
| -17% | -$47.4M | 0.05% | 397 |
|
|
2021
Q3 | $274M | Buy |
452,792
+96,267
| +27% | +$59.8M | 0.06% | 319 |
|
|
2021
Q2 | $199M | Sell |
356,525
-6,203
| -2% | -$3.14M | 0.04% | 409 |
|
|
2021
Q1 | $172M | Buy |
362,728
+127,994
| +55% | +$62.3M | 0.04% | 415 |
|
|
2020
Q4 | $113M | Sell |
234,734
-302,210
| -56% | -$163M | 0.03% | 554 |
|
|
2020
Q3 | $301M | Buy |
536,944
+41
| +0% | +$24.9K | 0.09% | 215 |
|
|
2020
Q2 | $335M | Buy |
536,903
+17,886
| +3% | +$10.2M | 0.1% | 185 |
|
|
2020
Q1 | $253M | Sell |
519,017
-159,339
| -23% | -$65.7M | 0.09% | 207 |
|
|
2019
Q4 | $255M | Buy |
678,356
+235,055
| +53% | +$79.1M | 0.06% | 318 |
|
|
2019
Q3 | $123M | Sell |
443,301
-163,168
| -27% | -$48.3M | 0.04% | 545 |
|
|
2019
Q2 | $190M | Buy |
606,469
+5,741
| +1% | +$1.91M | 0.05% | 388 |
|
|
2019
Q1 | $247M | Buy |
600,728
+89,862
| +18% | +$37M | 0.07% | 274 |
|
|
2018
Q4 | $191M | Sell |
510,866
-37,905
| -7% | -$13.9M | 0.06% | 326 |
|
|
2018
Q3 | $222M | Buy |
548,771
+41,589
| +8% | +$15.8M | 0.06% | 374 |
|
|
2018
Q2 | $175M | Sell |
507,182
-146,982
| -22% | -$46M | 0.05% | 457 |
|
|
2018
Q1 | $225M | Buy |
654,164
+154,823
| +31% | +$53.8M | 0.06% | 369 |
|
|
2017
Q4 | $188M | Buy |
499,341
+113,282
| +29% | +$45.9M | 0.04% | 477 |
|
|
2017
Q3 | $173M | Buy |
386,059
+13,792
| +4% | +$6.56M | 0.04% | 498 |
|
|
2017
Q2 | $183M | Buy |
372,267
+39,299
| +12% | +$17.2M | 0.05% | 450 |
|
|
2017
Q1 | $129M | Buy |
332,968
+5,452
| +2% | +$2.02M | 0.04% | 605 |
|
|
2016
Q4 | $120M | Sell |
327,516
-581,949
| -64% | -$221M | 0.03% | 658 |
|
|
2016
Q3 | $366M | Sell |
909,465
-5,235
| -0.6% | -$2.1M | 0.11% | 164 |
|
|
2016
Q2 | $319M | Buy |
914,700
+171,592
| +23% | +$66.1M | 0.1% | 174 |
|
|
2016
Q1 | $268M | Sell |
743,108
-92,514
| -11% | -$38.1M | 0.09% | 234 |
|
|
2015
Q4 | $454M | Buy |
835,622
+453,676
| +119% | +$246M | 0.14% | 133 |
|
|
2015
Q3 | $178M | Buy |
381,946
+29,957
| +9% | +$16.1M | 0.06% | 354 |
|
|
2015
Q2 | $180M | Buy |
351,989
+11,521
| +3% | +$5.62M | 0.06% | 378 |
|
|
2015
Q1 | $154M | Buy |
340,468
+119,764
| +54% | +$50.8M | 0.05% | 460 |
|
|
2014
Q4 | $90.5M | Sell |
220,704
-151,446
| -41% | -$59.6M | 0.03% | 721 |
|
|
2014
Q3 | $134M | Sell |
372,150
-787,522
| -68% | -$264M | 0.04% | 505 |
|
|
2014
Q2 | $328M | Buy |
1,159,672
+100,882
| +10% | +$29.9M | 0.1% | 193 |
|
|
2014
Q1 | $318M | Sell |
1,058,790
-214,574
| -17% | -$66.1M | 0.1% | 188 |
|
|
2013
Q4 | $350M | Buy |
1,273,364
+9,176
| +0.7% | +$2.64M | 0.12% | 173 |
|
|
2013
Q3 | $396M | Buy |
1,264,188
+27,790
| +2% | +$7.31M | 0.15% | 128 |
|
|
2013
Q2 | $278M | Buy |
+1,236,398
| New | +$288M | 0.11% | 184 |
|
Other funds holding REGN
VCM
N
Goldman Sachs's REGN Position: Q1 2026 in Review
Goldman Sachs increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, buying an estimated $156M and bringing the position to 1,300,558 shares worth $1B. The position accounts for 0.12% of the portfolio, ranked #168.
Goldman Sachs first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Goldman Sachs held 1,300,558 shares of Regeneron Pharmaceuticals worth $1B as of Q1 2026.
- Goldman Sachs bought 203,231 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $156M.
- Regeneron Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #168 holding.
- Goldman Sachs first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.